Although a majority of metastatic lesions to bone are lytic, a significant proportion of lesions contain both a lytic and blastic component. We have previously demonstrated that the cytokine profiles of cancer cells involved in the formation of osteolytic and osteoblastic lesions differ(1), and treatment strategies that inhibit the osteolytic or osteoblastic pathways can decrease the size of the metastatic lesions(2,3). BMP-2 and BMP-4 are aberrantly expressed in a non-small-cell lung cancer (NSCLC) line, and inhibition of BMP activity with its inhibitor noggin can result in a reduction of tumor growth and angiogenesis(4).
INTRODUCTION
Although a majority of metastatic lesions to bone are lytic, a significant proportion of lesions contain both a lytic and blastic component. We have previously demonstrated that the cytokine profiles of cancer cells involved in the formation of osteolytic and osteoblastic lesions differ (1) , and treatment strategies that inhibit the osteolytic or osteoblastic pathways can decrease the size of the metastatic lesions (2, 3) . BMP-2 and BMP-4 are aberrantly expressed in a non-small-cell lung cancer (NSCLC) line, and inhibition of BMP activity with its inhibitor noggin can result in a reduction of tumor growth and angiogenesis (4) .
The purpose of this study was to determine if blockade of key components in both the osteolytic and osteoblastic pathways would result in a reduction of a mixed osteolytic/osteoblastic NSCLC tumor size in a murine model of bony metastasis. We used a retroviral vector encoding noggin, the competitive inhibitor of BMP, to inhibit osteoblastic activity. A soluble chimeric protein (RANK:Fc) that was formed by fusing the four cysteine-rich domains of RANK with the Fc portion of human IgG1 was used to inhibit osteoclast activity.
METHODS
Cell Line: The NSCLC cell line A549 was used in this experiment. RANK:FC: RANK:Fc was administered to the treatment groups twice weekly with a subcutaneous injection of 15 mg/kg. Subcutaneous turmor formation: 1x10 5 A549 cells were placed on a 2 mm x 2 mm collagen sponge. A 3 mm longitudinal incision was made along the back of SCID mice. The collagen sponge was placed into this cavity, and the wound was closed. Tibial injection: 1x10 5 A549 cells were injected into the left tibia of SCID mice. A 27 ½ ga. needle was introduced into the proximal tibia, and the cells were injected into the cavity. A549 transduction: A549 cells were transduced with the noggin retrovirus cDNA (RN). 1x10 5 A549 cells were plated on a sterile culture dish in RPMI medium with 10% FBS. The cells were washed once with 1% PBS, and 2 ml fresh medium containing the retrovirus at an MOI of 100 was added to the cells. The cells were incubated overnight and harvested for tibial injection 24 hours after viral infection. The supernatants were preserved to assay for noggin production by Western blot. Experimental groups: There were 5 experimental evaluated, and each group underwent implantation of cells in a subcutaneous model and an intratibial injection (Table I ). There were 10 animals in each group. 
RESULTS
A549+RN resulted in significantly smaller subcutaneous tumor size at 8 weeks, although treatment with RANK:Fc had no effect. (Table II) . (Figure 1) . Treatment with RN, RANK:Fc, or both led to significantly smaller tumor size compared to A549 alone or A549+EV. (Figure 2) . Histomorphometry demonstrated that animals treated with A549+RN (Groups II and V) had significantly less osteoblasts/mm. Animals treated with A549+RANK:Fc (Groups IV and V) had significantly less osteoclasts/mm (Table III) . 19.5 ± 7.7%* 20.4 ± 4.5* 11.0 ± 2.1 A549+EV 36.7 ± 5.1% 32.1 ±2.8 9.7 ± 4.1 A549+RANK:Fc 52.3 ± 2.3%* 27.9 ± 3.9 0.8 ± 0.4* A549+RN+RANK:Fc 36.3 ± 4.7%
18.4 ± 4.2* 0.7 ± 0.4* BV/TV=bone volume/tissue volume; Ob/mm=osteoblasts/mm; Oc/mm=osteoclasts/mm. *=p<0.05 vs. A549.
DISCUSSION
Results from this study demonstrate that the NSCLC cell line A549 forms an mixed osteolytic/osteoblastic lesion in vivo, and overexpression of noggin or treatment with RANK:Fc significantly decreases the rate of tumor growth in vivo. Treatment with both modalities to inhibit both osteolytic and osteoblastic pathways was more effective than either treatment alone.
Despite the success of noggin and RANK:Fc in inhibiting the progression of A549 tumor size in a bone metastasis model, neither treatment alone was effective in completely inhibiting tumor progression. However, the combination of noggin and RANK:Fc was able to decrease tumor size to the size of the control uninjected tibia, and also inhibited the proliferation of A549 cells within the medullary canal, as seen with our histologic results. This data highlights the importance of both pathways in the development and progression of mixed osteoblastic/osteolytic metastatic lesions in bone. Blockade of the RANK:RANKL pathway decreases osteoclast number and likely also decreases the cytokines available to tumor cells, but it is unable to inhibit tumor cell proliferation. The results of this study suggest that successful treatment of metastatic disease needs to effect a variety of pathways including osteoblast activation and osteoclast activation.
